Asthma is one of the most common chronic airway diseases and is characterized by symptoms, such as, wheezing and coughing. Its prevalence in Korea is gradually increasing among children and adults, especially among those older than 60 years. In this study, we investigated the effects of ginsenoside Rg1 (Rg1), one of the major constituents of Panax ginseng Meyer on ovalbumin (OVA) plus Aspergillus protease (A. protease) allergen-induced asthmatic mice. Mice were orally administered Rg1 for 10 days from 8 days after OVA + A. protease sensitization and intranasally administered booster doses of OVA + A. protease for 4 days from 14 days after sensitization. The effects of Rg1 administration on airway hyperresponsiveness (AHR), immune cell distributions in bronchoalveolar lavage fluid (BALF), and serum level of immunoglobulin E (IgE) were investigated at 18 days after sensitization. Histopathological changes in hematoxylin and eosin (H&E)-stained lung sections were also examined. Treatment of OVA + A. protease-sensitized/challenged asthmatic mice with Rg1 significantly decreased total eosinophil counts in BALF as compared with those of phosphate-buffered saline (PBS)-treated sensitized/challenged controls, and significantly decreased methacholine-induced AHR. Furthermore, IgE serum levels were significantly lower in Rg1 administered OVA + A. proteasesensitized asthmatic mice than in PBS-treated sensitized/challenged controls. The study shows Rg1 protects against A. protease allergen-induced asthma in mice.
Allergic asthma is defined as a chronic respiratory disease characterized by airway inflammation, persistent airway hyperresponsiveness (AHR), and reversible airway obstruction. Airway inflammation in allergic asthma is believed to be caused by an imbalance between T helper type 1 and type 2 (Th1/Th2) cytokine activation, leading to immunoglobulin E (IgE) production and eosinophil recruitment in the respiratory tract [1, 2] .
In developed countries, typically 20-30% of general populations are affected by an allergic disease, such as, pollen allergies, eczema, or asthma [3] . But, unfortunately, only a few treatment options are available for those who have been using inhaled corticosteroids and β-agonists [3, 4] , and these options can be costly, provide only modest benefits, and have potentially serious side effects [4] .
In patients with asthma, exposure to fungal biomass can cause agedependent sensitization and asthmatic reactions, and Aspergillus species (A. spp.) are ubiquitous, spore-forming fungi that exacerbate cystic fibrosis and asthma ever growing numbers of patients [5, 6] .
Fungal exposure rarely causes disease, but the increased incidence of fungal-related occupational asthma is a cause of concern. Recent studies in environmental medicine have established a clear causal relationship between A. spp. and asthma, and indicate that the prevalence of adulthood asthma induced by fungi is increasing [7, 8] .
Ginseng Radix, the dried root of Panax ginseng Meyer (P. ginseng), a well-known medicinal herb, which is used as a complementary alternative medicine for treating asthma, allergies, and immunological conditions [9] [10] [11] . In fact, P. ginseng continues to be used as a general health promoting tonic in northeast Asia, and its pharmacological properties are believed to be derived from ginsenosides [12] .
Previously, we reported Korean red ginseng (RG) was more potent than Korean white ginseng (WG) at ameliorating symptoms, such as, inflammatory cell infiltration, AHR, and airway remodeling in an acute asthma model; an ovalbumin (OVA) + aluminum hydroxide (alum)-sensitized mouse model [13] , which is a widely to model allergic asthma and shows Th2 displaced immune response and elevated IgE levels [14] .
However, allergens, such as, house dust mites (HDM), cockroaches, and A. spp. that induce clinical asthma exhibit high protease activities, and thus, various endotoxins are considered more appropriate for the induction of allergic airway immune reactions, because they do so via mechanisms that differ from that in the OVA + alum-sensitized murine asthmatic model [15] [16] [17] [18] .
Generally, fungal spores are rapidly removed from the lungs, but exposure to large numbers can induce allergic sensitization [19] . Thus, in this study, we investigated the effects of ginsenoside Rg1 Eosinophils are prominent feature in lung tissues of asthma and are circulating granulocytes that participate in the induction of AHR and remodeling, which characterize asthma. Promising treatments for asthma aim at reducing eosinophil infiltration into the bronchoalveolar region in cases of allergic pulmonary inflammation [1, 2, 8, 20] . We evaluated the effect of Rg1 on eosinophilic inflammatory cell numbers in bronchoalveolar lavage fluid (BALF) ( Figure 2A ). We found numbers of macrophages, eosinophils, neutrophils, and lymphocytes were significantly elevated in the BALF samples of PBS (phosphate-buffered saline)-treated sensitized controls as compared with the PBS-treated sensitized controls, and that treatment with Rg1 significantly reduced total inflammatory cell and eosinophil numbers ( Figure 2B ). Furthermore, Rg1 showed a tendency to decrease numbers of inflammatory cells in a dose dependent manner. In PBS-treated sensitized/challenged controls, inflammatory cells were observed to infiltrate respiratory tracts more than in PBStreated sensitized controls (Figure 3 ). These changes were observed, although the alveolar lesion was washed with cold (4°C) PBS to obtain the BALF. In Rg1-treated mice, respiratory tract inflammatory cell infiltration was milder than that in PBS-treated sensitized/challenged controls.
To determine whether Rg1 affects methacholine inhalation-induced AHR, a methacholine bronchial asthma test and whole-body plethysmography were used to measure enhanced pause (Penh) values. AHR in PBS-treated sensitized/challenged controls was significantly higher than in PBS-treated sensitized controls ( Figure  4 ). Rg1 treatment significantly decreased Penh values as compared with PBS-treated sensitized/challenged controls. Immunological responses in asthma are characterized by the activation of Th2-related allergic responses, including immunoglobulin E (IgE) synthesis, which is strongly associated with asthma [21] [22] [23] . In PBS-treated sensitized/challenged controls, a remarkable significant increase in OVA-specific IgE levels was observed in serum, and Rg1 treatment significantly reduced these increases ( Figure 5 ). Treatment to naïve T cells (Th0), ginsenoside Rg1 was reported to enhance the expression of IL-4 mRNA on CD4 + T cells which suggests Rg1 promotes Th2 lineage development [24] , whereas when Rg1 was administered to rats with lipopolysaccharide (LPS) induced inflammation, key mediators of the development of Th2 response, such as, tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and IL-6 expressions were suppressed in macrophages [25] . Thus, further studies on the action mechanisms of Rg1 are provided.
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Natural Product Communications Vol. 13 (4) 2018 417 In summary, we investigated the effects of Rg1 on airway inflammation, AHR to methacholine, and on serum IgE levels in OVA + A. protease-sensitized/challenged asthmatic mice. Rg1 significantly suppressed inflammatory cell infiltration into bronchoalveolar regions, and AHR to methacholine in OVA + A. protease-sensitized/challenged asthmatic mice was ameliorated by Rg1 treatment. Furthermore, serum levels of IgE (an important biomarker of asthma) were significantly reduced by Rg1. The present study shows Rg1 has potential use as a natural antiasthmatic agent in the complementary and alternative medicine fields.
Experimental
Animal groups and Rg1 treatment: Five-week-old male BALB/c mice were purchased from Samtako Co., (Gyeonggi Province, Korea), and maintained in the animal facility of Pusan National University (PNU) School of Korean Medicine. All experimental animal protocols were approved by the ethics committee of PNU (approval number; PNU-2012-0017). The mice were allocated to five experimental groups. PBS-treated sensitized controls (n=6) were OVA + A. protease-sensitized but not challenged and administered PBS as vehicle. PBS-treated sensitized/challenged controls (n=6) were sensitized, challenged, and administered PBS as vehicle. The Rg1 groups (n=8, respectively) mice were sensitized, challenged, and administered Rg1 (10, 30, or 100 mg/kg daily per os, respectively). Rg1 was dissolved in dimethylsulfoxide (DMSO), diluted with PBS and filtered through a syringe filter of pore size 0.45-μm before injection.
HPLC analysis of Rg1:
The analysis was performed using a Shimadzu HPLC (Shimadzu, Japan) equipped with LC-20AD pumps, a SPD-M20A detector, and a Phenomenex Luna C18 column (5 μm, 150 mm × 4.6 mm). Chromatographic separation was accomplished using a mobile phase of acetonitrile-water (volume ratio, 1:4) at a flow rate of 1.0 mL/min. Sensitization and challenge with A. protease antigen: Mice were sensitized and challenged using a modification of the method previously described by Hogaboam [26] . Briefly (Figure 1 ), Freund's adjuvant (F5881, Sigma-Aldrich, MO, USA) containing chicken egg OVA was reconstituted in 1 mg/mL sterile PBS and stored at -20°C. The mice administered intraperitoneal injections of 10 μL (10 μg) A. protease containing 40 μL adjuvant for sensitization. Two weeks after sensitization, 10 μL A. protease containing 40 μL adjuvant was intranasally administered to each designated mouse for 5 consecutive days as booster doses to localize allergic inflammation in airways. AHR to methacholine was measured the day after the last challenge. Mice were euthanized on the same day (day 15). BALF cells were harvested, and number and types of cells were counted.
Measurement of AHR:
Airway functions were evaluated using the methacholine bronchial asthma test. Whole body plethysmography (OCP 3000, Allmedicus, Gyounggi, Korea) was used to measure AHR by increasing methacholine doses (Sigma-Aldrich, MO, USA) administered using an ultrasonic nebulizer (Pari, Starnberg, Germany). Changes were calculated using enhanced pause (Penh) values (a major indicator of airway obstruction). Each dose of aerosolized methacholine was administered for 150 s.
Analysis of BALF:
After measuring AHR, the mice were euthanized with CO 2 , and BALF was collected from tracheas to determine inflammatory cells distribution patterns in airways. Briefly, in each case, the trachea was exposed, cut just under the larynx, and then a flexible polyurethane tube was inserted, and lungs were rinsed twice with ice cold PBS. BAL was performed using 800 μL PBS, and the average amount returned was ~500 μL. BALF was centrifuged at 4°C for 10 min at 1,000×g, and cell pellets were suspended in ice-cold PBS and then centrifuged on microscope slides for 10 min at 500×g using a cytospin. The slides were air-dried and treated with Diff-Quik solution (Sysmex, Kobe, Japan) to stain inflammatory cells, which were then fixed and mounted on slides. Differential inflammatory cell counts of lymphocytes, neutrophils, and eosinophils were obtained using an optical microscope.
Histopathological study: After obtaining BALF, the mouse lung tissues were harvested, fixed in 4% paraformaldehyde, paraffin embedded and sectioned at 5-µm. Lung sections were mounted on glass slides and stained with hematoxylin and eosin (H&E). The images were visualized and acquired using a ZEISS Axio microscope (Carl Zeiss, Germany) and the ZEISS Axio application.
Measurement of serum IgE level:
Blood samples were collected from mice on day 19 after sensitization, stored overnight at 4°C, and then centrifuged at 2,800×g for 10 min to obtain serum. Serum IgE levels were measured using an ELISA (enzyme-linked immunosorbent assay) kit (BD Pharmingen, CA, USA).
